Foghorn Therapeutics, Inc. (FHTX): Price and Financial Metrics

Foghorn Therapeutics, Inc. (FHTX): $13.05

0.95 (+7.85%)

POWR Rating

Component Grades













Add FHTX to Watchlist
Sign Up

Industry: Biotech



in industry


  • Growth is the dimension where FHTX ranks best; there it ranks ahead of 63.95% of US stocks.
  • FHTX's strongest trending metric is Growth; it's been moving up over the last 179 days.
  • FHTX ranks lowest in Momentum; there it ranks in the 4th percentile.

FHTX Stock Summary

  • Foghorn Therapeutics Inc's stock had its IPO on October 23, 2020, making it an older stock than merely 2.27% of US equities in our set.
  • FHTX's price/sales ratio is 470.43; that's higher than the P/S ratio of 99.17% of US stocks.
  • As for revenue growth, note that FHTX's revenue has grown 206.74% over the past 12 months; that beats the revenue growth of 96.15% of US companies in our set.
  • If you're looking for stocks that are quantitatively similar to Foghorn Therapeutics Inc, a group of peers worth examining would be INO, ABUS, ALPN, MGNX, and CLLS.
  • FHTX's SEC filings can be seen here. And to visit Foghorn Therapeutics Inc's official web site, go to

FHTX Valuation Summary

  • In comparison to the median Healthcare stock, FHTX's price/earnings ratio is 115.34% lower, now standing at -5.6.
  • Over the past 45 weeks, FHTX's price/sales ratio has gone NA NA.
  • Over the past 45 weeks, FHTX's price/sales ratio has gone NA NA.

Below are key valuation metrics over time for FHTX.

Stock Date P/S P/B P/E EV/EBIT
FHTX 2021-08-31 481.8 4.6 -5.6 -5.2
FHTX 2021-08-30 454.0 4.3 -5.3 -4.9
FHTX 2021-08-27 449.5 4.3 -5.2 -4.8
FHTX 2021-08-26 417.6 4.0 -4.9 -4.4
FHTX 2021-08-25 395.7 3.8 -4.6 -4.2
FHTX 2021-08-24 389.7 3.7 -4.6 -4.1

FHTX's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • FHTX has a Quality Grade of C, ranking ahead of 42.73% of graded US stocks.
  • FHTX's asset turnover comes in at 0.005 -- ranking 410th of 682 Pharmaceutical Products stocks.
  • 500 - Internal server error

The table below shows FHTX's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.005 1 -0.469
2020-12-31 0.003 1 -0.581

FHTX Price Target

For more insight on analysts targets of FHTX, see our FHTX price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $25.67 Average Broker Recommendation 1.38 (Strong Buy)

FHTX Stock Price Chart Interactive Chart >

Price chart for FHTX

FHTX Price/Volume Stats

Current price $13.05 52-week high $24.34
Prev. close $12.10 52-week low $8.01
Day low $12.05 Volume 88,900
Day high $13.28 Avg. volume 162,106
50-day MA $13.14 Dividend yield N/A
200-day MA $13.53 Market Cap 541.16M

Foghorn Therapeutics, Inc. (FHTX) Company Bio

Foghorn Therapeutics, Inc. operates as a development stage biopharmaceutical company. It is discovering and developing a novel class of precision medicine therapeutics targeting the chromatin regulatory system in oncology. Through its scalable Gene Traffic Control product platform, the firm is systematically interrogating and drugging the chromatin regulatory system. The company was founded by Cigall Kadoch, Gerald W. Crabtree and Douglas G. Cole in October 2015 and is headquartered in Cambridge, MA.

FHTX Latest News Stream

Event/Time News Detail
Loading, please wait...

FHTX Latest Social Stream

Loading social stream, please wait...

View Full FHTX Social Stream

Latest FHTX News From Around the Web

Below are the latest news stories about Foghorn Therapeutics Inc that investors may wish to consider to help them evaluate FHTX as an investment opportunity.

How Much Upside is Left in Foghorn Therapeutics Inc. (FHTX)? Wall Street Analysts Think 26%

The consensus price target hints at a 25.6% upside potential for Foghorn Therapeutics Inc. (FHTX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Yahoo | January 12, 2022

Foghorn Therapeutics Inc. (FHTX) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now

Foghorn Therapeutics Inc. (FHTX) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.

Yahoo | January 11, 2022

Foghorn Therapeutics Announces Chief Scientific Officer Succession

CAMBRIDGE, Mass., Jan. 10, 2022 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a company pioneering the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system, announced Steven Bellon, Ph.D., currently Senior Vice President of Drug Discovery, is promoted to Chief Scientific Officer, effective today, January 10, 2022. Carl Decicco, Ph.D., is retiring from his role as Chief Scientific Officer at Fog

Yahoo | January 10, 2022

Foghorn Therapeutics to Participate at the H.C. Wainwright BioConnect Conference

CAMBRIDGE, Mass., Jan. 07, 2022 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a company pioneering the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system, today announced that Foghorn will present at the H.C. Wainwright BioConnect Conference which is being held virtually on January 10th through the 13th, 2022. With an initial focus in oncology, Foghorn’s Gene Traffic Control Platform and resu

Yahoo | January 7, 2022

Zacks: Analysts Expect Foghorn Therapeutics Inc. (NASDAQ:FHTX) Will Post Quarterly Sales of $330,000.00

Equities research analysts expect that Foghorn Therapeutics Inc. (NASDAQ:FHTX) will post sales of $330,000.00 for the current quarter, according to Zacks Investment Research. Two analysts have issued estimates for Foghorn Therapeutics earnings, with the highest sales estimate coming in at $500,000.00 and the lowest estimate coming in at $150,000.00. The firm is scheduled to issue []

Dakota Financial News | December 22, 2021

Read More 'FHTX' Stories Here

FHTX Price Returns

1-mo 6.53%
3-mo 33.30%
6-mo 5.41%
1-year 25.36%
3-year N/A
5-year N/A
YTD -42.94%
2021 12.83%
2020 N/A
2019 N/A
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.6822 seconds.